Table 6.
Biochemical characteristics and treatment outcomes of patients with GH excess from the literature review.
| Patient No. | Pretreatment | Tx for GH excess | Posttreatment | Visual defect | Hearing and olfactory defects | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| GH nadir(µg/L) | IGF-1Z-score | PRL(µg/L) | ALP(IU/L) | IGF-1Z-score | ALP(IU/L) | GH excesscontrolled | ||||
| 1 | 8.21 | 8.1 | 3,218 | 216 | DA | NA | NA | NA | Bitemporal hemianopia | NA |
| 2 | NA | 14.8 | 155.8 | 2,259 | LAR+PEG | NA | NA | NA | Left eye dystopia | NA |
| 3 | NA | 2.0 | 24.9 | NA | LAR+DA | NA | NA | No | NA | NA |
| 4 | NA | 2.0 | 20 | NA | LAR+DA | NA | NA | Yes | NA | NA |
| 5 | NA | 4.5 | 4.43 | NA | LAR+DA | NA | NA | No | NA | NA |
| 6 | NA | 1.8 | NA | 715 | LAR+DA+PEG | −2.8 | 515 | Yes | NA | NA |
| 7 | 40.5 | 6.2 | 26 | NA | Surgery | 1 | NA | PR | Unilateral blindness | Deafness |
| 8 | 127 | 8.8 | 17 | NA | Surgery | −2.4 | NA | Yes | NA | NA |
| 9 | NA | 6.0 | 285.3 | 690 | DA | NA | 417 | Yes | Mild left-sided hemianopia | NA |
| 10 | NA | 3.0 | NA | NA | LAR+DA+PEG | −1 | NA | Yes | NA | NA |
| 11 | NA | 17.7 | 38.5 | NA | 2 surgeries + LAR + DA | 3.6 | NA | PR | NA | NA |
| 12 | 3.4 | 3.0 | 177 | 537.9 | Surgery + LAR + DA | 2.3 | NA | PR | NA | NA |
| 13 | NA | 2.3 | 18.9 | 8721 | LAR | −0.3 | 6,870 | PR | Bitemporal upper quarter blindness | NA |
| 14 | NA | 8.3 | 18 | NA | RT+PEG | 0.7 | NA | Yes | NA | NA |
| 15 | 12.5 | NA | NA | NA | LAR | NA | NA | NA | Normal | Normal |
| 16 | 26 | NA | NA | 812 | LAR | NA | PR | Binasal visual field loss | NA | |
| 17 | 1.2 | 1.8 | 20 | 1224 | LAR+DA+PEG | −2.5 | 970 | Yes | Normal | Normal |
| 18 | 60.2 | 8.2 | 81.5 | 474 | LAR+DA/PEG | 3 | 366 | PR | Blindness | Hearing loss |
| 19 | 14.3 | 4.6 | 98 | 871 | LAR+DA/PEG | 1.1 | 833 | Yes | Normal | Normal |
| 20 | 16.2 | 3.2 | 27 | NA | LAR | NA | NA | NA | Normal | Normal |
| 21 | 29 | >5 | 53 | NA | DA | NA | NA | NA | Normal | Normal |
| 22 | 2.3 | −0.2 | 36 | NA | None | NA | NA | NA | Normal | Normal |
| 23 | 5.3 | 2.5 | 17 | NA | LAR | NA | NA | NA | Normal | Hearing loss |
| 24 | 16.3 | >5 | 68 | NA | DA+LAR | NA | NA | NA | Normal | Hearing loss |
| 25 | NA | 3.9 | 206.7 | 256 | LAR | 1.4 | NA | PR | NA | NA |
| 26 | 37 | 12.1 | 62.1 | NA | Surgery+LAR | 4.6 | NA | PR | NA | NA |
| 27 | 11 | 8.1 | 35 | 1,105 | LAR | NA | NA | NA | NA | NA |
| 28 | 4.9 | 9.4 | 14.6 | NA | RT+LAR | NA | NA | PR | Normal | NA |
| 29 | NA | NA | 27–33 | NA | Sandostatin+DA | NA | No | NA | NA | |
| 30 | NA | NA | NA | NA | Surgery | NA | NA | NA | Bitemporal hemianopsia | NA |
| 31 | 10.4 | NA | 46.1 | NA | DA | – | No | NA | NA | |
| 32 | NA | NA | 66 | NA | Sandostatin+DA | NA | NA | NA | Normal | NA |
| 33 | 5.4 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 34 | NA | NA | >200 | NA | Surgery+DA | NA | NA | No | NA | NA |
| 35 | 170 | NA | 190 | 2,500 | Surgery | – | – | Dead | Visual defect | Hearing loss |
| 36 | 5 | NA | 45.6 | 285 | NA | NA | NA | NA | Right eye optic atrophy | Normal |
| 37 | 98 | NA | NA | NA | NA | NA | NA | NA | Normal | NA |
| 38 | NA | NA | NA | NA | Fractionated radiotherapy | NA | NA | NA | Left temporal hemianopsia | NA |
| 39 | 5.3 | NA | 86.9 | NA | DA | NA | NA | PR | Normal | Normal |
GH, growth hormone; IGF-1, insulin-like growth factor-1; PRL, prolactin; ALP, alkaline phosphatase; Macro, macroadenoma; Micro, microadenoma; LAR, long-acting somatostatin analogue octreotide; DA, dopamine agonist; PEG, pegvisomant.